INTEGRATIVE INSIGHTS
ON EMERGING OPPORTUNITIES

Integrative research means our extensive company research informs every thesis and perspective. The result is deep industry knowledge, expertise, and trend insights that yield valuable results for our partners and clients.

First Analysis Healthcare Technology Team
Matthew Nicklin
Managing Director
Andrew Walsh
Managing Director
Joseph Munda
Vice President
Tracy Marshbanks
Managing Director
Healthcare IT
AHIP highlights favorable trends for transparency and precision medicine
June 23, 2015
  • Transparency and precision medicine were the two major themes at the 2015 AHIP Institute conference we attended earlier this month in Nashville.
  • We highlight a few emerging private companies in both areas, but most of our discussion focuses on the broader population health market, encompassing precision medicine and the goal to make treatment decisions on an individualized basis down to the DNA and even peptide level with technology from companies such as NantHealth.
  • With respect to transparency, we continue to see a need for improved sources of quality information to complement cost data; the market is being led by independent companies (vs. insurers) focused on a different segment of the market, including Castlight Health (self-insured employers), HealthSparq (health plans), and Theranos (lab testing).

TABLE OF CONTENTS

Includes profiles of 10 public and private companies

Population health a critical area of investment

Precision medicine

Transparency

Analytics

INTRODUCTION

Two major themes, transparency and precision medicine, emerged from the 2015 AHIP (America’s Health Insurance Plans) Institute conference we attended in Nashville in early June. As evidenced by an ongoing list of new initiatives such as the Clear Choices Campaign, a coalition of prominent employers and insurers promoting transparency, and the Pharmaceutical Cost Transparency Act of 2015, a proposal in California that would require drug makers to report profits and production expenses for any drug or course of treatment costing $10,000 or more, transparency efforts continue to show strong momentum.

This momentum is likely to increase with a rise in healthcare costs. After historically slower growth rates in recent years, healthcare spending is now accelerating at higher-than-expected rates. U.S. healthcare spending increased by 7.2% in Q1 2015 compared with the same period last year, driven in large part by higher spending among hospitals (up 9.2%), according to data from the Census Bureau’s Quarterly Services Survey. This backdrop is a positive for Castlight Health, which is focused on self-insured employers, and HealthSparq, the leading vendor focused on health plans. As a further sign of progress, in late May, Castlight filed an 8-K disclosing a process by which it can obtain a customer’s plan information from UnitedHealth to allow Castlight to provide its services to that customer. During a panel discussion at the conference, AmeriHealth also indicated its desire to be transparent and provide third parties access to AmeriHealth’s data, but it is moving cautiously given concerns about how this information will be used.

Our conversations with some of the leading population health vendors suggest sales activity has significantly accelerated since the start of 2015, and we expect the winning vendors in the broader market will be the independents offering a technology-driven solution (ZeOmega, Wellcentive, and Kryptiq) or outsourced-driven solutions (Evolent Health, Valence Health, and xG Health), not the EHR vendors (Allscripts, Quality Systems, and athenahealth) who are aggressively entering the market. Furthermore, the payers (vs. the providers) appear to be moving faster and have experience managing risk as well as the financial wherewithal to subsidize the cost of these initiatives.

©2024 by First Analysis Corporation.
One South Wacker Drive
  ·  
Suite 3900
  ·  
Chicago, IL 60606
  ·  
312-258-1400